Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

Abstract The increasing use of multiple immunomodulatory (IMD) agents for cancer therapies (e.g. antibodies targeting immune checkpoints, bispecific antibodies, and chimeric antigen receptor [CAR]-T cells), is raising questions on their potential immunogenicity and effects on treatment. In this revi...

Full description

Bibliographic Details
Main Authors: Jasmine Davda, Paul Declerck, Siwen Hu-Lieskovan, Timothy P. Hickling, Ira A. Jacobs, Jeffrey Chou, Shahram Salek-Ardakani, Eugenia Kraynov
Format: Article
Language:English
Published: BMJ Publishing Group 2019-04-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
ADA
Antibody
Immunogenicity
Immunomodulatory
Neutralizing antibodies
PD-1/PD-L1
Online Access:http://link.springer.com/article/10.1186/s40425-019-0586-0

Internet

http://link.springer.com/article/10.1186/s40425-019-0586-0

Similar Items